Phaseline

Companies › Skylark Bio

Skylark Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SKY-GJB2
Gene therapy replacing GJB2 (Connexin 26)
GJB2Phase 1GJB2-mediated Hearing LossDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07627971SKY-GJB2Phase 1GJB2-mediated Hearing LossOtherDec 2027

Targets

GJB2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.